[{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"bd95cf3a-a05b-4e87-b03d-357c3daa7c72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04628767","created_at":"2021-01-29T07:21:36.268Z","updated_at":"2025-02-25T12:37:42.651Z","phase":"Phase 2/3","brief_title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","source_id_and_acronym":"NCT04628767","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 249","initiation":"Initiation: 11/12/2021","start_date":" 11/12/2021","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"5634cce6-a08c-4073-971b-86089c97d96d","acronym":"CATALINA-2","url":"https://clinicaltrials.gov/study/NCT06690775","created_at":"2025-02-25T14:11:51.367Z","updated_at":"2025-02-25T14:11:51.367Z","phase":"Phase 2","brief_title":"CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","source_id_and_acronym":"NCT06690775 - CATALINA-2","lead_sponsor":"TORL Biotherapeutics, LLC","biomarkers":" CLDN6 • PROC","pipe":"","alterations":" ","tags":["CLDN6 • PROC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ixotatug vedotin (TORL-1-23) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 11/20/2024","start_date":" 11/20/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"99c4032a-3714-4351-a6af-2208fcba233e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684368","created_at":"2021-01-19T20:47:18.675Z","updated_at":"2025-02-25T15:11:50.245Z","phase":"Phase 2","brief_title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","source_id_and_acronym":"NCT04684368","lead_sponsor":"Children's Oncology Group","biomarkers":" NF1","pipe":" | ","alterations":" AFP elevation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/13/2021","start_date":" 07/13/2021","primary_txt":" Primary completion: 12/21/2029","primary_completion_date":" 12/21/2029","study_txt":" Completion: 12/21/2029","study_completion_date":" 12/21/2029","last_update_posted":"2025-02-13"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"76e5fabc-947c-4440-ba90-48fba05bcaa1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01850888","created_at":"2021-01-18T08:15:43.798Z","updated_at":"2025-02-25T16:51:18.108Z","phase":"","brief_title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","source_id_and_acronym":"NCT01850888","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" IL6 • IL2","pipe":"","alterations":" ","tags":["IL6 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Azedra (iobenguane I 131)"],"overall_status":"Suspended","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-04"},{"id":"6d86e75b-88c2-4211-b30c-f46071399e7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01933932","created_at":"2021-01-17T17:38:54.654Z","updated_at":"2025-02-25T17:22:15.826Z","phase":"Phase 3","brief_title":"Assess Efficacy \u0026 Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","source_id_and_acronym":"NCT01933932","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Koselugo (selumetinib) • Neulasta (pegfilgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 510","initiation":"Initiation: 09/25/2013","start_date":" 09/25/2013","primary_txt":" Primary completion: 06/07/2016","primary_completion_date":" 06/07/2016","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-31"},{"id":"b4947302-8201-4385-90e7-1045ddc21de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220022","created_at":"2021-01-18T15:53:27.752Z","updated_at":"2025-02-25T17:29:32.862Z","phase":"Phase 1","brief_title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","source_id_and_acronym":"NCT03220022","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 06/20/2025","study_completion_date":" 06/20/2025","last_update_posted":"2025-01-30"},{"id":"aad15df4-1ae3-483a-b0fd-2eaad8e9fe6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06520176","created_at":"2025-02-27T07:53:36.469Z","updated_at":"2025-02-27T07:53:36.469Z","phase":"Phase 3","brief_title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","source_id_and_acronym":"NCT06520176","lead_sponsor":"The Affiliated People's Hospital of Ningbo University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • etoposide IV • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-25"},{"id":"8867cfc4-6361-4173-9d43-50e658b88b64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03943901","created_at":"2021-01-18T19:25:09.596Z","updated_at":"2024-07-02T16:34:27.599Z","phase":"Phase 2","brief_title":"Split-Dose R-CHOP for Older Adults With DLBCL","source_id_and_acronym":"NCT03943901","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 02/17/2021","start_date":" 02/17/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-10"},{"id":"da3993b4-3224-43f3-abf3-1a2b44201eaf","acronym":"TINKS","url":"https://clinicaltrials.gov/study/NCT05634369","created_at":"2023-12-20T08:17:53.968Z","updated_at":"2024-07-02T16:34:37.915Z","phase":"Phase 1/2","brief_title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","source_id_and_acronym":"NCT05634369 - TINKS","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" TGFB1 • TGFBI","pipe":"","alterations":" ","tags":["TGFB1 • TGFBI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • dexamethasone • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-05"},{"id":"3bb3cbaf-b275-4098-8e50-b212d3de0ff5","acronym":"cRIB","url":"https://clinicaltrials.gov/study/NCT05645718","created_at":"2022-12-09T14:57:54.671Z","updated_at":"2024-07-02T16:35:06.157Z","phase":"Phase 2","brief_title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05645718 - cRIB","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • Neulasta (pegfilgrastim) • Depocyte (liposomal cytarabine)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-05-03"},{"id":"95fe996a-08c8-4bbd-9a80-6d6d99bc679d","acronym":"REFRaME-O1","url":"https://clinicaltrials.gov/study/NCT05870748","created_at":"2023-05-23T16:06:11.980Z","updated_at":"2024-07-02T16:35:08.676Z","phase":"Phase 2/3","brief_title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","source_id_and_acronym":"NCT05870748 - REFRaME-O1","lead_sponsor":"Sutro Biopharma, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression • FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"},{"id":"1903d6da-d5c7-43b4-a343-51787a604398","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070564","created_at":"2021-01-18T00:10:47.683Z","updated_at":"2024-07-02T16:35:09.760Z","phase":"Phase 3","brief_title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT00070564","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3294","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 01/01/2015","primary_completion_date":" 01/01/2015","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-04-15"},{"id":"399a3c18-8af0-4750-ba3d-cf958723ee45","acronym":"","url":"https://clinicaltrials.gov/study/NCT01046825","created_at":"2021-01-18T04:06:42.768Z","updated_at":"2024-07-02T16:35:09.908Z","phase":"Phase 2/3","brief_title":"Mature B-Cell Lymphoma And Leukemia Study III","source_id_and_acronym":"NCT01046825","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • prednisone • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 09/09/2010","start_date":" 09/09/2010","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-04-12"},{"id":"d9205d85-be27-4b6c-84a5-c85c6627b25a","acronym":"NCI-2018-01198","url":"https://clinicaltrials.gov/study/NCT03136146","created_at":"2021-01-18T15:27:28.397Z","updated_at":"2024-07-02T16:35:12.329Z","phase":"Phase 2","brief_title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","source_id_and_acronym":"NCT03136146 - NCI-2018-01198","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-03-29"},{"id":"87bcd5d7-65b9-43a1-8517-f0ede1fe83cf","acronym":"NEUTHREE","url":"https://clinicaltrials.gov/study/NCT05949333","created_at":"2023-07-20T15:09:13.325Z","updated_at":"2024-07-02T16:35:17.796Z","phase":"Phase 4","brief_title":"Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy","source_id_and_acronym":"NCT05949333 - NEUTHREE","lead_sponsor":"Eunseong Medical Foundation Good GANG-AN HOSPITAL","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Rolvedon (eflapegrastim-xnst)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-23"},{"id":"fc93aba5-8861-4b10-9446-12fded8ce082","acronym":"MC078E","url":"https://clinicaltrials.gov/study/NCT00670358","created_at":"2021-01-18T02:30:11.467Z","updated_at":"2024-07-02T16:35:25.345Z","phase":"Phase 1/2","brief_title":"Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma","source_id_and_acronym":"NCT00670358 - MC078E","lead_sponsor":"Mayo Clinic","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Neulasta (pegfilgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 08/25/2008","start_date":" 08/25/2008","primary_txt":" Primary completion: 05/07/2021","primary_completion_date":" 05/07/2021","study_txt":" Completion: 11/11/2024","study_completion_date":" 11/11/2024","last_update_posted":"2023-12-22"},{"id":"807674cf-1bc0-43eb-bae4-f7928e8936a0","acronym":"Pro00011685","url":"https://clinicaltrials.gov/study/NCT02834403","created_at":"2021-01-18T13:54:35.762Z","updated_at":"2024-07-02T16:35:26.085Z","phase":"Phase 1/2","brief_title":"L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT02834403 - Pro00011685","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • ER negative • PGR negative","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Neulasta (pegfilgrastim) • tilarginine (L-NMMA) • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2023-12-15"},{"id":"22596f08-9a13-45d8-aa0e-b548af9dec06","acronym":"","url":"https://clinicaltrials.gov/study/NCT02728531","created_at":"2021-01-18T13:21:23.644Z","updated_at":"2024-07-02T16:35:30.887Z","phase":"Phase 1","brief_title":"Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02728531","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD20 • CCND1 • CD34","pipe":" | ","alterations":" CD20 expression • CD19 expression • CCND1 expression","tags":["CD20 • CCND1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD19 expression • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • bendamustine • Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/18/2016","start_date":" 04/18/2016","primary_txt":" Primary completion: 01/16/2019","primary_completion_date":" 01/16/2019","study_txt":" Completion: 08/16/2023","study_completion_date":" 08/16/2023","last_update_posted":"2023-11-01"},{"id":"26065744-c262-4f87-91b1-e6294c2cfbc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04323956","created_at":"2021-01-18T20:56:54.236Z","updated_at":"2024-07-02T16:35:31.265Z","phase":"Phase 1","brief_title":"Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT04323956","lead_sponsor":"Mayo Clinic","biomarkers":" MYC • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression • CD20 expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • parsaclisib (INCB50465) • Polivy (polatuzumab vedotin-piiq) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2023-10-30"},{"id":"cd1393a5-991e-4bdb-9e0d-cdba3e37115a","acronym":"IMpassion031","url":"https://clinicaltrials.gov/study/NCT03197935","created_at":"2021-01-17T17:20:58.112Z","updated_at":"2024-07-02T16:35:31.579Z","phase":"Phase 3","brief_title":"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT03197935 - IMpassion031","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 07/24/2017","start_date":" 07/24/2017","primary_txt":" Primary completion: 04/03/2020","primary_completion_date":" 04/03/2020","study_txt":" Completion: 09/28/2022","study_completion_date":" 09/28/2022","last_update_posted":"2023-10-26"},{"id":"e40ed8d7-48ac-41b5-b29f-5f77dd399916","acronym":"","url":"https://clinicaltrials.gov/study/NCT05032183","created_at":"2023-08-14T10:11:06.622Z","updated_at":"2024-07-02T16:35:33.498Z","phase":"Phase 1/2","brief_title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05032183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/17/2022","start_date":" 02/17/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-16"},{"id":"1edc2e61-bcd5-42c9-88f7-a4d3a80395fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909036","created_at":"2021-01-18T14:16:39.145Z","updated_at":"2024-07-02T16:35:35.026Z","phase":"Phase 1","brief_title":"Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.","source_id_and_acronym":"NCT02909036","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Neulasta (pegfilgrastim) • captisol-enabled melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-03"}]